Olema Pharmaceuticals, Inc. OLMA 深 滬
等待開盤 09-30 09:30:00 美东时间
9.54
+0.030
+0.32%
華盛通- 最 高9.77
- 今 開9.50
- 成交量 116.93万股
- 最 低 9.2572
- 昨 收 9.51
- 總市值 6.55亿
- 52周最高 13.51
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 2.86
- 委 比 -48.65%
- 總股本 6863.43万
- 歷史最高 60.27
- 量 比 1.14
- 振 幅 5.39%
- 歷史最低 2.00
- 每 手 1
- 風險率 2.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
The outlook for the KAT6 inhibitors market is strengthening as interest in epig...
09-17 05:31
SA Asks: Which biotechs could be acquired by year's end?
The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked Seeking Alpha analysts Stephen Ayers ...
09-14 04:18
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Pfizer collaboration with Olema may spark future bidding war - analyst
Olema Pharmaceutical's (NASDAQ:OLMA) announcement of a new clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) in metastatic breast cancer may be a sign of a potential bidding war...
09-04 03:26
Oppenheimer Maintains Outperform on Olema Pharmaceuticals, Maintains $22 Price Target
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price target.
09-04 02:55
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Pharmaceuticals, Inc., a biopharmaceutical company focused on developing targeted therapies for breast cancer, announced its participation in several upcoming investor conferences in September 2025. The events include fireside chats and presentations in Boston and New York. Olema is advancing a pipeline of novel therapies, including palazestrant (OP-1250), a Phase 3 clinical trial candidate, and OP-3136, a Phase 1 study drug. More informati...
08-20 20:30
Olema Pharmaceuticals shares are trading higher. The company reported Q2 financial results.
Olema Pharmaceuticals shares are trading higher. The company reported Q2 financ...
08-12 21:00
Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target from $20 to $21.
08-12 19:28
Olema Pharmaceuticals Q2 EPS $(0.51) Misses $(0.38) Estimate
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.38) by 35.64 percent. This is a 5.56 percent increase over losses of $(0.54) per share
08-12 04:14
